Back to Search
Start Over
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study
- Source :
- The Lancet Haematology; January 2016, Vol. 3 Issue: 1 pe12-e21, 10p
- Publication Year :
- 2016
-
Abstract
- The efficacy and safety of the anticoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been shown in phase 3 trials. However, data about rivaroxaban use in routine clinical practice are needed.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 3
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs37417142
- Full Text :
- https://doi.org/10.1016/S2352-3026(15)00257-4